Tinnion Robert J, Embleton Nicholas D
Newcastle Neonatal Service, Newcastle upon Tyne, UK.
Arch Dis Child Educ Pract Ed. 2012 Aug;97(4):157-63. doi: 10.1136/archdischild-2012-301633. Epub 2012 Jul 3.
Alkaline phosphatase (ALP) is regularly measured in clinical practice. Changes in serum levels are observed in a number of clinical conditions. In neonatology, it has been proposed as a useful marker for both a diagnosis and an indication of the severity of metabolic bone disease (MBD) in infants born preterm. Nutritional practices, aimed at reducing the occurrence or severity of MBD, have led to ALP being proposed as a stand-alone means of monitoring treatment. The current evidence does not support this use: ALP only achieves usefulness in a diagnostic and monitoring capacity when combined with other serum and imaging techniques.
碱性磷酸酶（ALP）在临床实践中经常进行检测。在许多临床病症中都可观察到血清水平的变化。在新生儿学领域，有人提出它可作为诊断和提示早产婴儿代谢性骨病（MBD）严重程度的有用标志物。旨在减少MBD发生或严重程度的营养措施，使得ALP被提议作为一种独立的治疗监测手段。目前的证据并不支持这种用法：只有与其他血清和影像学技术结合使用时，ALP才在诊断和监测方面具有效用。
